Healthcare Industry News: Roche
News Release - June 5, 2013
Peter J. Carbonaro Joins Atossa Genetics as Senior Vice President of OperationsSEATTLE, WA--(Healthcare Sales & Marketing Network) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Peter J. Carbonaro has joined the Company as Senior Vice President of Operations, a newly created position. Mr. Carbonaro's primarily focus and responsibilities include regulatory, quality, manufacturing, supply chain, IT, Facilities and Human Resources. He reports to Dr. Steven Quay, Chairman, CEO & President.
A veteran diagnostic/medical device/biotechnology industry decision maker, Mr. Carbonaro brings more than 30 years' experience in process development, supply chain and manufacturing. This includes expertise in product development, technology transfer, manufacturing and supply chain at a number of prominent companies including Gilead Sciences and Hoffmann LaRoche as well as several early stage companies.
"The Company is very fortunate to have Peter Carbonaro join us as at this pivotal time as we continue to ramp up sales and manufacturing of our ForeCYTE Breast Health Test," said Dr. Quay. "Peter's extensive industry experience and in-depth operations and manufacturing expertise will be invaluable in helping us make the ForeCYTE test available to millions of women across America."
"Atossa Genetics has the potential to change the way we think about breast cancer risk assessment and prevention and I am excited to join the Atossa team to help make the ForeCYTE test and other products and services developed by the Company become the standard of care," said Mr. Carbonaro. "I am honored to join the Atossa team to drive our success for the benefit of women in the fight against breast cancer."
Prior to joining Atossa Genetics, Mr. Carbonaro (54) served as Vice President, Operations, at Ondine Biomedical, Inc. from 2011 to 2013. From 2006 to 2011, Mr. Carbonaro served in increasingly responsible positions at Gilead Sciences, Inc., including Director of Manufacturing in Seattle, Washington; Director of Manufacturing in Ireland; Director of Global Operational Excellence, Pharmaceutical Manufacturing and Senior Director, Pharmaceutical Manufacturing. Earlier, Mr. Carbonaro served from 2001 to 2006 as Senior Director of Manufacturing for Corus Pharma, which was acquired by Gilead Sciences in 2006. From 1997 to 2001, Mr. Carbonaro was Vice President of Operations at Bartel, Inc., which was later acquired by Trinity Biotech.
Mr. Carbonaro began his career at Roche Diagnostic Systems, Inc., Belleville, New Jersey, where he served as Production Manager, Senior Group Leader and Associate Scientist. Mr. Carbonaro also served as Vice President of Operations and Director of Operations at Aprogenix, Inc., based in Houston, prior to joining Bartels.
Mr. Carbonaro holds an MBA in Organizational Behavior from Iona College and a BS degree in biology from Siena College.
On June 3, 2013, and as an inducement to cause Mr. Carbonaro to join the Company, he was awarded an option to purchase a total of 250,000 shares of common stock of the Company, par value $0.001 per share, 163,000 of which are outside the Company's 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.58 per share, the fair market value on the grant date and vests over a four-year period from his commencement of service. This stock option was granted as an inducement material to Mr. Carbonaro's entering into employment with the Company and is being reported in accordance with NASDAQ Listing Rule 5635(c)(4).
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.
The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.
For additional information on Atossa and the ForeCYTE test, please visit www.atossagenetics.com. For additional information on the National Reference Laboratory for Breast Health, please visit www.nrlbh.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Source: Atossa Genetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.